Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers

Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system

Shiladitya Sengupta, David A. Eavarone, Ishan Capila et al. · Nature · 2005 · 943 citations

Pharmacy, Oncology, Pharmaceutics +16

Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.

P. Vasey, Stan B. Kaye, Rachel Morrison et al. · PubMed · 1999 · 691 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

Effect of Vascular Normalization by Antiangiogenic Therapy on Interstitial Hypertension, Peritumor Edema, and Lymphatic Metastasis: Insights from a Mathematical Model

Ricky T. Tong, Lance L. Munn · Cancer Research · 2007 · 620 citations · Full text

Medicine, Oncology, Pharmacology +17

In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy

Paul Tardi, Sharon A. Johnstone, Natashia Harasym et al. · Leukemia Research · 2008 · 354 citations

Medicine, Pharmacokinetics, Pharmacology +8

Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470

Ronit Satchi‐Fainaro, Mark Puder, John W. Davies et al. · Nature Medicine · 2004 · 345 citations

Pharmacy, Molecular Pharmaceutics, Oncology +12